The Framingham Heart Study – Global Impact, Ongoing Influence
A Special Issue of Progress in Cardiovascular Diseases
Philadelphia, PA, July 6, 2010 – Few medical investigations have had the impact of the Framingham Heart Study. This study, started in 1948, was designed as a cohort, observational study of cardiovascular disease, then recognized as a growing health threat but now has emerged as much more. The Framingham Heart study came to revolutionize thinking about cardiovascular disease, change the study of epidemiology, and even force the biostatistics community to develop multivariate analysis. In a special issue of Progress in Cardiovascular Diseases, leaders from around the world offer their views on the global impact of the Framingham Heart Study.
The issue includes 10 articles describing not only the historical background of the Framingham Study, but also some of the current public health programs around the world that grew out of Framingham. An interview with Dr. William Kannel, one of the principal investigators, provides a personal perspective on this monumental work."
From the insights developed over the 60+ years of this still-ongoing study, significant investigations show the continuing influence of Framingham. Dr. Pekka Puska describes the Finnish-North Karelia project, the most potent demonstration that behavioral alteration in lifestyle risk factors leads to improved cardiovascular outcomes. Dr. K. Srinath Reddy describes a wide-reaching public health initiative to combat an explosive emergence of cardiovascular disease in India and Southeast Asia. In another program based on the legacy of Framingham, Drs. Cother Hajat and Oliver Harrison describe their comprehensive survey of over 95% of the Abu Dhabi population to develop a nation-wide prevention program for both the native citizens and the immigrant communities.
“The now well-established risk factor concept, fundamental to prevention of CVD, originated from the Framingham study,” commented Shanthi Mendis, MD, of the World Health Organization. “It generated seminal findings such as the effects of tobacco use, unhealthy diet, physical inactivity, obesity, raised blood cholesterol, raised blood pressure, and diabetes on CVD. When these findings were first published, these were novel cardiovascular risk factors, now they are the major focus for global and national prevention efforts for reducing the burden of CVD and other major noncommunicable diseases. The Framingham Heart Study has also been in the forefront of the development of cardiovascular risk prediction equations for assessment of absolute risk.”
The true global impact of the Framingham Heart Study, according to Henry Greenberg, MD, St. Luke's Roosevelt Hospital Center, New York, NY, and Editor-in-Chief of Progress in Cardiovascular Diseases, is whether prevention works. “The final verdict on the efficacy and relevance of the Framingham Heart Study is the outcome. Altering behavioral or cultural or political determinants of risk does reduce the societal burden of CVD. In the United States, though lacking a top-down approach to public health, the dramatic fall in CVD mortality in the early 1960s when little but blood pressure control was available speaks to this. During the ensuing 40 years, about half of the 50% fall in CVD mortality is attributable to prevention and risk factor modification, the legacy of the Framingham Heart Study.”
# # #
Notes To Editors
These articles appear in a special issue of Progress in Cardiovascular Diseases, The Global Impact of the Framingham Heart Study, Volume 53, Number 1, (July/August 2010), published by Elsevier.
Full text of the articles is available to journalists upon request. Contact Katrina Saling at Elsevier, 215-239-3712, firstname.lastname@example.org, to obtain copies.
Journalists wishing to set up interviews should contact Henry Greenberg, MD, Editor-in-Chief, Progress in Cardiovascular Diseases, Associate Professor of Clinical Medicine & Faculty, Institute of Human Nutrition, Columbia University College of Physicians and Surgeons, Associate Director, Cardiology, St. Luke's Roosevelt Hospital, New York, NY 10019, Tel: 212-523-7370, email@example.com.
PROGRESS IN CARDIOVASCULAR DISEASES, Vol. 53, No. 1, July/August 2010
TABLE OF CONTENTS
The Global Impact of the Framingham Heart Study: Editor’s Introduction
Preface—Global Impact of the Framingham Heart Study
Peter W.F. Wilson
Interview of William Kannel, MD
Peter Wilson, Henry Greenberg
The Contribution of the Framingham Heart Study to the Prevention
of Cardiovascular Disease: A Global Perspective
From Framingham to North Karelia: From Descriptive Epidemiology
to Public Health Action
The Framingham Heart Study: Impact on the Prevention and Control
of Cardiovascular Diseases in India
Kolli Srinath Reddy, Ambika Satija
The Abu Dhabi Cardiovascular Program: The Continuation of Framingham
Cother Hajat, Oliver Harrison
Blood Pressure and Cardiovascular Disease: Tracing the Steps
Fiona Turnbull, Andre Pascal Kengne, Stephen MacMahon
The Framingham Study, Diabetes Mellitus and Cardiovascular Disease:
Turning Back the Clock
Andre Pascal Kengne, Fiona Turnbull, Stephen MacMahon
From Framingham to the Framework Convention on Tobacco Control
Framingham Heart Study: The First 20 Years
Gerald M. Oppenheimer
Deciphering the Causes of Cardiovascular and Other Complex Diseases in
Populations: Achievements, Challenges, Opportunities, and Approaches
Salim Yusuf, Sonia Anand
The Framingham Heart Study’s Impact on Global Risk Assessment
Asaf Bitton, Thomas Gaziano
About Progress in Cardiovascular Diseases
Each issue of Progress in Cardiovascular Diseases (www.onlinepcd.com) comprehensively covers a single topic in the understanding and treatment of disorders of the heart and circulation. Some issues include special articles, definitive reviews that capture the state of the art in the management of particular clinical problems in cardiology.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com